Clinical trials: Adenovirus
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Anthrax Infection
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.
- Trial name
- NCT01979406
- Testing
- AVA, Ad4-PA-1, Ad4-PA-GPI-1
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to compare the humoral immune response induced by 3 different batches of Ad26.ZEBOV as measured by enzyme - linked immunosorbent assay (ELISA) against the Ebola virus (EBOV) GP (Glycoprotein) at 56…
- Trial name
- NCT02543268
- Testing
- Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3
- Where
- 6 sites in United States
- Volunteers
- 329 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
COVID-19
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or…
- Trial name
- NCT05067933
- Testing
- VXA-CoV2-1.1-S
- Where
- 4 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
Healthy, HIV Infections
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
This study will test the safety and side effects of an experimental vaccine booster against HIV. A vaccine is a substance given to try to create immunity or resistance to a disease or infection.
- Trial name
- NCT00102089
- Testing
- VRC-HIVADV014-00-VP booster, VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infection, Adenovirus Infection
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation
Invasive infections with CMV and Adenovirus, not responding to virostatic treatment are treated with virusspecific donor derived or autologous virusspecific T-cells.
- Trial name
- VISIT (NCT02702427)
- Testing
- virus-specific T-Cells
- Where
- Austria
- Sponsor
- St. Anna Kinderkrebsforschung
Adenovirus
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
BACKGROUND: The 243 amino acid E1A encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein , an apoptosis inducing protein, and as…
- Trial name
- NCT03325517
- Volunteers
- 50 people
- Sponsor
- Heba Momen kamel
Seasonal Influenza B
Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza B tested at two dose levels…
- Trial name
- NCT02547792
- Testing
- VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine
- Where
- New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Glioblastoma Multiforme, Recurrent Tumor
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
Phase I trial, unicentric, uncontrolled. Intratumoral injection or intramural (into the resected tumor cavity) of DNX2401 into brain tissue will be followed by up to two 28 - day cycles of oral temozolomide (TMZ) in schedule of 7…
- Trial name
- D24GBM (NCT01956734)
- Testing
- DNX2401 and Temozolomide
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
HIV Infections
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00618605
- Testing
- Ad26.ENVA.01 HIV-1 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malignant Glioma of Brain, Glioblastoma
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and…
- Trial name
- HGG-01 (NCT00870181)
- Testing
- ADV-TK/GCV, Surgery, systemic chemotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Huazhong University of Science and Technology
Adenovirus
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV)…
- Trial name
- AdAPT (NCT03339401)
- Testing
- Standard of Care, Brincidofovir
- Where
- 36 sites in United States, France and 7 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
HPV-Associated Cancers
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
This is a Phase 1/1b open-label dose escalation trial of Ad/MG1-E6E7 and sequential treatment with atezolizumab in patients with HPV associated cancers. This study will consist of two arms.
- Trial name
- Kingfisher (NCT03618953)
- Testing
- Ad-E6E7, MG1-E6E7, Atezolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Turnstone Biologics, Corp.
Lip and Oral Cavity Cancer, Oropharyngeal Cancer
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx.
- Conditions
- Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer
- Trial name
- NCT00064103
- Testing
- Ad5CMV-p53 gene, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Covid19
Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV
A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate the efficacy, safety and immunogenicity of one or two doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18…
- Trial name
- COVID-19 (NCT05005156)
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
- Where
- 4 sites in Argentina
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Cystic Fibrosis
Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, in patients with…
- Trial name
- NCT00004779
- Testing
- Ad5-CB-CFTR
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Pancreatic Cancer
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer.
- Trial name
- NCT02705196
- Testing
- delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Lokon Pharma AB
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.